30142 South Wixom road
Wixom, MI 48393
United States
248 960 9009
https://www.rockwellmed.com
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 237
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Mark Strobeck Ph.D. | President, CEO & Director | 904,66k | N/D | 1971 |
Mr. Jesse Neri | Senior Vice President of Finance | 359,63k | N/D | 1978 |
Ms. Megan C. Timmins | Executive VP, Chief Legal Officer & Secretary | 585,74k | N/D | 1973 |
Mr. James A. McCarthy | Senior Vice President of Business & Corporate Development | N/D | N/D | N/D |
Mr. Timothy T. Chole | Senior Vice President of Sales & Marketing | N/D | N/D | N/D |
Ms. Heather R. Hunter | Senior VP & Chief Corporate Affairs Officer | N/D | N/D | N/D |
Mr. Jason Finkelstein | Investor Relations Representative | N/D | N/D | N/D |
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
L'ISS Governance QualityScore di Rockwell Medical, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.